{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:11:59Z","timestamp":1781835119747,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MSD Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuromuscular blocking (NMB) agents are often administered to facilitate tracheal intubation and prevent patient movement during surgical procedures requiring the use of general anesthetics. Incomplete reversal of NMB, can lead to residual NMB, which can increase the risk of post-operative pulmonary complications. Sugammadex is indicated to reverse neuromuscular blockade induced by rocuronium or vecuronium in adults. The aim of this study is to estimate the clinical and economic impact of introducing sugammadex to routine reversal of neuromuscular blockade (NMB) with rocuronium in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A decision analytic model was constructed reflecting a set of procedures using rocuronium that resulted in moderate or deep NMB at the end of the procedure. Two scenarios were considered for 537,931 procedures using NMB agents in Spain in 2015: a scenario without sugammadex versus a scenario with sugammadex. Comparators included neostigmine (plus glycopyrrolate) and no reversal agent. The total costs for the healthcare system were estimated from the net of costs of reversal agents and overall cost offsets via reduction in postoperative pneumonias and atelectasis for which incidence rates were based on a Spanish real-world evidence (RWE) study. The model time horizon was assumed to be one year. Costs were expressed in 2019 euros (\u20ac) and estimated from the perspective of a healthcare system. One-way sensitivity analysis was carried out by varying each parameter included in the model within a range of +\/\u2212\u200950%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The estimated budget impact of the introduction of sugammadex to the routine reversal of neuromuscular blockade in Spanish hospitals was a net saving of \u20ac57.1 million annually. An increase in drug acquisition costs was offset by savings in post-operative pulmonary events, including 4806 post-operative pneumonias and 13,996 cases of atelectasis. The total cost of complications avoided was \u20ac70.4 million. All parameters included in the model were tested in sensitivity analysis and were favorable to the scenario with sugammadex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This economic analysis shows that sugammadex can potentially lead to cost savings for the reversal of rocuronium-induced moderate or profound NMB compared to no reversal and reversal with neostigmine in the Spanish health care setting. The economic model was based on data obtained from Spain and from assumptions from clinical practice and may not be valid for other countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12871-021-01248-2","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T01:17:55Z","timestamp":1613783875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Economic impact of improving patient safety using Sugammadex for routine reversal of neuromuscular blockade in Spain"],"prefix":"10.1186","volume":"21","author":[{"given":"J.","family":"Martinez-Ubieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Arag\u00f3n- Bened\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cea-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cedillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ram\u00edrez-Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Pascual-Bellosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"crossref","unstructured":"Boon M, Martini C, Dahan A. Recent advances in neuromuscular block during anesthesia. F1000Res. 2018;9(7):167.","DOI":"10.12688\/f1000research.13169.1"},{"key":"1248_CR2","doi-asserted-by":"crossref","unstructured":"Green MS, Venkatesh AG, Venkataramani R. Management of Residual Neuromuscular Blockade Recovery: Age-Old Problem with a New Solution. Case Rep Anesthesiol. 2017:8197035.","DOI":"10.1155\/2017\/8197035"},{"key":"1248_CR3","doi-asserted-by":"crossref","unstructured":"Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010;27:874\u201381.","DOI":"10.1097\/EJA.0b013e32833d56b7"},{"key":"1248_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1213\/ANE.0b013e3181da832d","volume":"111","author":"GS Murphy","year":"2010","unstructured":"Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111:120\u20138.","journal-title":"Anesth Analg"},{"issue":"1","key":"1248_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1213\/01.ANE.0000095040.36648.F7","volume":"98","author":"GS Murphy","year":"2004","unstructured":"Murphy GS, Szokol JW, Franklin M, Marymont JH, Avram MJ, Vender JS. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. Anesth Analg. 2004;98(1):193\u2013200.","journal-title":"Anesth Analg"},{"key":"1248_CR6","unstructured":"Bissinger U, Schimek F, Lenz G. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium. Physiol Res. 2000;49(4):455\u201362."},{"issue":"4","key":"1248_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/00000542-200004000-00014","volume":"92","author":"E Sundman","year":"2000","unstructured":"Sundman E, Witt H, Olsson R, et al. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000;92(4):977\u201384.","journal-title":"Anesthesiology."},{"key":"1248_CR8","doi-asserted-by":"crossref","unstructured":"Eriksson LI. Residual neuromuscular blockade. Incidence and relevance. Anaesthesist. 2000;49 Suppl 1: S18\u2013S19.","DOI":"10.1007\/s001010070008"},{"issue":"6","key":"1248_CR9","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/00000542-200306000-00006","volume":"98","author":"M Eikermann","year":"2003","unstructured":"Eikermann M, Groeben H, H\u00fcsing J, et al. Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade. Anesthesiology. 2003;98(6):1333\u20137.","journal-title":"Anesthesiology."},{"issue":"4","key":"1248_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/00000542-199704000-00005","volume":"86","author":"AF Kopman","year":"1997","unstructured":"Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology. 1997;86(4):765\u201371.","journal-title":"Anesthesiology."},{"issue":"1","key":"1248_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12871-016-0281-3","volume":"16","author":"RP Insinga","year":"2016","unstructured":"Insinga RP, Joyal C, Goyette A, et al. A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada. BMC Anesthesiol. 2016;16(1):114.","journal-title":"BMC Anesthesiol"},{"key":"1248_CR12","doi-asserted-by":"crossref","unstructured":"Esteves S, Martins M, Barros F, et al. Incidence of postoperative residual neuromuscular blockade in the postanaesthesia care unit: An observational multicentre study in portugal. Eur J Anaesthesiol. 2013;30(05):243\u20139.","DOI":"10.1097\/EJA.0b013e32835dccd7"},{"key":"1248_CR13","unstructured":"Bridion Product label. Available on: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bridion-epar-product-information_en.pdf. Accessed Feb 2020."},{"key":"1248_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/ACO.0b013e32833a5413","volume":"23","author":"C Rex","year":"2010","unstructured":"Rex C, Bergner UA, Puhringer FK. Sugammadex: a selective relaxant-binding agent providing rapid reversal. Curr Opin Anaesthesiol. 2010;23:461\u20135.","journal-title":"Curr Opin Anaesthesiol"},{"key":"1248_CR15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4172\/2155-6148.1000140","volume":"2","author":"D Sabo","year":"2011","unstructured":"Sabo D, Jones RK, Berry J, et al. Residual neuromuscular blockade at extubation: a randomized comparison of sugammadex and neostigmine reversal of rocuronium-induced blockade in patients undergoing abdominal surgery. J Anesthes Clin Res. 2011;2:140.","journal-title":"J Anesthes Clin Res"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/bja\/aen037","volume":"100","author":"EA Flockton","year":"2008","unstructured":"Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008;100:622\u201330.","journal-title":"Br J Anaesth"},{"key":"1248_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1213\/ane.0b013e3181ac53c3","volume":"110","author":"KS Khuenl-Brady","year":"2010","unstructured":"Khuenl-Brady KS, Wattwil M, Vanacker BF, et al. Sugammadex provides faster reversal of vecuronium induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010;110:64\u201373.","journal-title":"Anesth Analg"},{"issue":"2","key":"1248_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1213\/ANE.0000000000000757","volume":"121","author":"LP Fortier","year":"2015","unstructured":"Fortier LP, McKeen D, Turner K, et al. The RECITE study: A canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade. Anesth Analg. 2015;121(2):366\u201372.","journal-title":"Anesth Analg"},{"key":"1248_CR19","unstructured":"Batistaki C, Tentes P, Deligiannidi P, et al. Residual neuromuscular blockade in a real-life clinical setting. Correlation with sugammadex or neostigmine administration. Minerva Anestesiol. 2015:22."},{"key":"1248_CR20","doi-asserted-by":"crossref","unstructured":"Ledowski T, O'Dea B, Meyerkort L, et al. Postoperative residual neuromuscular paralysis at an australian tertiary children's hospital. Anesthesiol Res Pract. 2015:410248.","DOI":"10.1155\/2015\/410248"},{"issue":"1","key":"1248_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bjan.2012.06.003","volume":"66","author":"I Aytac","year":"2016","unstructured":"Aytac I, Postaci A, Aytac B, et al. Survey of postoperative residual curarization, acute respiratory events and approach of anesthesiologists. Braz J Anesthesiol. 2016;66(1):55\u201362.","journal-title":"Braz J Anesthesiol"},{"issue":"6","key":"1248_CR22","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1213\/01.ANE.0000151159.55655.CB","volume":"100","author":"GS Murphy","year":"2005","unstructured":"Murphy GS, Szokol JW, Marymont JH, et al. Residual paralysis at the time of tracheal extubation. Anesth Analg. 2005;100(6):1840\u20135.","journal-title":"Anesth Analg"},{"issue":"2","key":"1248_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1213\/01.ane.0000195543.61123.1f","volume":"102","author":"G Cammu","year":"2006","unstructured":"Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006;102(2):426\u20139.","journal-title":"Anesth Analg"},{"issue":"3","key":"1248_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/bja\/ael386","volume":"98","author":"M Naguib","year":"2007","unstructured":"Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: A meta-analysis. Br J Anaesth. 2007;98(3):302\u201316.","journal-title":"Br J Anaesth"},{"key":"1248_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jclinane.2018.12.042","volume":"55","author":"L Saager","year":"2018","unstructured":"Saager L, Maiese EM, Bash LD, et al. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study. J Clin Anesth. 2018;55:33\u201341.","journal-title":"J Clin Anesth"},{"issue":"12","key":"1248_CR26","first-page":"1267","volume":"82","author":"CL Errando","year":"2016","unstructured":"Errando CL, Garutti I, Mazzinari G, et al. Residual neuromuscular blockade in the postanesthesia care unit: observational cross-sectional study of a multicenter cohort. Minerva Anestesiol. 2016;82(12):1267\u201377.","journal-title":"Minerva Anestesiol"},{"issue":"7","key":"1248_CR27","first-page":"735","volume":"82","author":"J Martinez-Ubieto","year":"2016","unstructured":"Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex. Minerva Anestesiol. 2016;82(7):735\u201342.","journal-title":"Minerva Anestesiol"},{"key":"1248_CR28","doi-asserted-by":"crossref","unstructured":"Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10(5):336\u201347.\u00a0","DOI":"10.1111\/j.1524-4733.2007.00187.x"},{"key":"1248_CR29","unstructured":"Conjunto m\u00ednimo b\u00e1sico de datos de Hospitalizaci\u00f3n 2015. Available on http:\/\/pestadistico.inteligenciadegestion.msssi.es\/publicoSNS\/comun\/DefaultPublico.aspx. Accessed Dec 2019."},{"issue":"3","key":"1248_CR30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.23736\/S0375-9393.16.11489-0","volume":"83","author":"BL Olesnicky","year":"2017","unstructured":"Olesnicky BL, Traill C, Marroquin-Harris FB. The effect of routine availability of sugammadex on postoperative respiratory complications: a historical cohort study. Minerva Anestesiol. 2017;83(3):248\u201354.","journal-title":"Minerva Anestesiol"},{"key":"1248_CR31","volume-title":"Bloqueo muscular residual y sus complicaciones en pacientes revertidos con neostigmina vs. sugammadex. III Congreso Nacional de rehabilitaci\u00f3n multimodal","author":"C Arag\u00f3n","year":"2018","unstructured":"Arag\u00f3n C, Martinez-Ubieto J, Ortega S, et al. Bloqueo muscular residual y sus complicaciones en pacientes revertidos con neostigmina vs. sugammadex. III Congreso Nacional de rehabilitaci\u00f3n multimodal. Salamanca: I GERM International Perioperative Medicine Congress; 2018."},{"key":"1248_CR32","unstructured":"BOTPLUS Portalfarma: Colegio Oficial de Farmac\u00e9uticos. Available on: https:\/\/botplusweb.portalfarma.com\/. Accessed Feb 2020."},{"key":"1248_CR33","unstructured":"Bolet\u00edn Oficial del Estado (BOE) Real Decreto-ley 8\/2010. Available on: https:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010-8228.pdf. Accessed Feb 2020."},{"key":"1248_CR34","unstructured":"Oblikue eSalud: Informaci\u00f3n econ\u00f3mica del sector sanitario. Available on: http:\/\/esalud.oblikue.com\/. Accessed May 2020."},{"key":"1248_CR35","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1399-6576.1997.tb04851.x","volume":"41","author":"RJ Berg h","year":"1997","unstructured":"Berg h RJ, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997;41:1095\u2013103.","journal-title":"Acta Anaesthesiol Scand"},{"key":"1248_CR36","doi-asserted-by":"crossref","unstructured":"Cappellini I, Ostento D, Loriga B, et al. Comparison of neostigmine vs. sugammadex for recovery of muscle function after neuromuscular block by means of diaphragm ultrasonography in microlaryngeal surgery: A randomised controlled trial. Eur J Anaesthesiol. 2020;37(1):44\u201351.","DOI":"10.1097\/EJA.0000000000001055"},{"key":"1248_CR37","doi-asserted-by":"crossref","unstructured":"Chambers D, Paulden M, Paton F, et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess. 2010;14(39):1\u2013211.","DOI":"10.3310\/hta14390"},{"key":"1248_CR38","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0310057X1204000219","volume":"40","author":"T Ledowski","year":"2012","unstructured":"Ledowski T, Hillyard S, Kozman A, et al. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anaesth Intensive Care. 2012;40:340\u20133.","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"1248_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/ACO.0b013e32834f012d","volume":"25","author":"Fuschs-Buder","year":"2012","unstructured":"Fuschs-Buder, Meistelman C, Schreiber JU. Is sugammadex economically viable for routine use. Curr Opin Anaesthesiol. 2012;25(2):217\u201320.","journal-title":"Curr Opin Anaesthesiol"},{"key":"1248_CR40","unstructured":"Mandim BL, Fonseca NM. Economic evaluation of the use of sugammadex in procedures under general anesthesia in Brazil. Am Soc Anesthesiol Annu Meet. 2011:A 121. Available at \u00a0http:\/\/www.asaabstracts.com\/strands\/asaabstracts\/abstract.htm?year=2011&index=7&absnum=6320."},{"key":"1248_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/bja\/aeq269","volume":"105","author":"F Paton","year":"2010","unstructured":"Paton F, Paulden M, Chambers D. Sugammadex compared with neostigmina\/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth. 2010;105:558\u201367.","journal-title":"Br J Anaesth"},{"key":"1248_CR42","doi-asserted-by":"crossref","unstructured":"Ozdemir O, Bahar M, Aypar U, et al. Cost-effectiveness analysis comparing Bridion\u00ae (Sugammadex) with neostigmine and spontaneous recovery in the reversal of neuromuscular blockade induced by rocuronium\/vecuronium. ISPOR 13th European Meeting International Society for Pharmacoeconomics and Outcomes Research Annual European Congress, Nov 6-9-2010 Prague, Czech Republic. Value in Health 2010 Abstract PND22.","DOI":"10.1016\/S1098-3015(11)72603-1"},{"key":"1248_CR43","volume-title":"An\u00e1lisis de los resultados obtenidos durante la pr\u00e1ctica cl\u00ednica habitual en la reversi\u00f3n del bloqueo neuromuscular superficial con Sugammadex. Valoraci\u00f3n de su impacto farmacoecon\u00f3mico. Thesis, University of Murcia","author":"LI Ripoll-Coronado","year":"2014","unstructured":"Ripoll-Coronado, LI; An\u00e1lisis de los resultados obtenidos durante la pr\u00e1ctica cl\u00ednica habitual en la reversi\u00f3n del bloqueo neuromuscular superficial con Sugammadex. Valoraci\u00f3n de su impacto farmacoecon\u00f3mico. Thesis, University of Murcia. 2014. Available at: http:\/\/hdl.handle.net\/10201\/40926. Accessed 30 Jul 2019."},{"issue":"12","key":"1248_CR44","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/anae.13277","volume":"70","author":"A Abad-Gurumeta","year":"2015","unstructured":"Abad-Gurumeta A, Ripoll\u00e9s-Melchor J, Casans-Franc\u00e9s R, et al. Evidence Anaesthesia Review Group. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015;70(12):1441\u201352.","journal-title":"Anaesthesia."},{"key":"1248_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinane.2016.06.018","volume":"35","author":"M Carron","year":"2016","unstructured":"Carron M, Zarantonello F, Tellaroli P, et al. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth. 2016;35:1\u201312.","journal-title":"J Clin Anesth"},{"key":"1248_CR46","first-page":"CD012763","volume":"8","author":"AM Hristovska","year":"2017","unstructured":"Hristovska AM, Duch P, Allingstrup M, et al. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8:CD012763.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-021-01248-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12871-021-01248-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-021-01248-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T03:25:18Z","timestamp":1671333918000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-021-01248-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1186\/s12871-021-01248-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-45449\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-45449\/v1","asserted-by":"object"}]},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Access to non-publicly available databases used in the analysis (eSalud and BotPlus) were obtained by subscription. This was a non-clinical study that did not collect information from individuals, and ethic committee approval or informed consent was not necessary.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MSD Spain and Merck & Co. employees participated in the model design, analysis, interpretation of data and writing of the manuscript. JY is employee of MSD Ltd., UK, and may own stock and\/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. PJ, RBP and CCL are employees of MSD, Spain. CS is an employee of Covance Clinical Development, a contract research organization providing support to MSD, Spain. MUJ, ABC, PBAM and MA declare NO competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}